BioXcel Therapeutics (BTAI) Receivables - Net (2019 - 2026)

BioXcel Therapeutics' Receivables - Net history runs 6 years deep, the most recent figure standing at $216000.0 for Q1 2026.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $216000.0 in Q1 2026; TTM through Mar 2026 was $216000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $233000.0, up 77.86% from the prior year.
• Receivables - Net retreated to $216000.0 in Q1 2026 per BTAI's latest filing, from $233000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $812000.0 in Q2 2024 and bottomed at $3000.0 in Q3 2024.
• The 5-year median for Receivables - Net is $240500.0 (2022), against an average of $296500.0.
• Biggest YoY gain for Receivables - Net was 88.4% in 2024; the steepest drop was 99.59% in 2024.
• Year by year, Receivables - Net stood at $248000.0 in 2022, then plunged by 71.37% to $71000.0 in 2023, then soared by 84.51% to $131000.0 in 2024, then surged by 77.86% to $233000.0 in 2025, then fell by 7.3% to $216000.0 in 2026.
• Per Business Quant, the three latest BTAI Receivables - Net figures stand at $216000.0 (Q1 2026), $233000.0 (Q4 2025), and $17000.0 (Q2 2025).